A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia

Trial Profile

A Randomized, Double Blind, Placebo Controlled, Multicenter Phase 2 Study of VT-122 in Combination With Sorafenib Compared to Sorafenib With Placebo in Patients With Hepatocellular Carcinoma and Systemic Inflammation at Risk for Cachexia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Propranolol/etodolac (Primary) ; Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors Vicus Therapeutics
  • Most Recent Events

    • 08 Dec 2015 Planned End Date changed from 1 Nov 2014 to 1 Apr 2016 as reported by ClinicalTrials.gov.
    • 16 Jan 2015 Results were presented at the 2015 Gastrointestinal Cancers Symposium, according to a Vicus Therapeutics media release.
    • 16 Jan 2015 Results published in a Vicus Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top